Efficacy and safety of insulin glargine 300 U/mL in people with T2D in China: the INITIATION study

被引：0
|
作者：
Chen, L. [1 ,2 ]
Wan, H. [3 ]
Han, J. [4 ]
Yang, C. [5 ]
Shao, H. [6 ]
Li, J. [7 ]
Yan, W. [8 ]
Zhang, M. [9 ]
Li, M. [10 ]
Han, Y. [10 ]
Kang, L. [10 ]
机构：
[1] Chu Hsien I Mem Hosp, Tianjin Key Lab Metab Dis, NHC Key Lab Hormones & Dev, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Inst Endocrinol, Dept Endocrinol, Tianjin, Peoples R China
[3] Panjin Cent Hosp, Dept Endocrinol, Panjin, Peoples R China
[4] Hebei PetroChina Cent Hosp, Dept Endocrinol, Langfang, Peoples R China
[5] Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Dept Endocrinol, Qingyuan, Peoples R China
[6] Nankai Univ, Tianjin Ctr Hosp 4, Dept Endocrinol, Tianjin, Peoples R China
[7] Ningbo Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Ningbo, Peoples R China
[8] Huadu Dist Peoples Hosp Guangzhou, Dept Endocrinol, Guangzhou, Peoples R China
[9] Sanofi Investment Co Ltd, Med RWE, Shanghai, Peoples R China
[10] Sanofi Investment Co Ltd, Med Diabet, Shanghai, Peoples R China
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2024年 / 209卷
关键词：
D O I：
10.1016/j.diabres.2024.111432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF23-0184
引用
收藏
页数：1
相关论文
共 50 条
  • [21] REAL-WORLD EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML (GLA-300) IN OLDER ADULTS (≥70 YEARS) WITH TYPE 2 DIABETES (T2D): ATOS STUDY SUBGROUP ANALYSIS
    Galstyan, G.
    Tirosh, A.
    Vargas-Uricoechea, H.
    Mabunay, M. A. N.
    Coudert, M.
    Pilorget, V.
    Khan, N.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A102 - A102
  • [22] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang L.
    Bosnyak, Zsolt
    Preblick, Ron
    Westerbacka, Jukka
    Gupta, Rishab
    Blonde, Lawrence
    DIABETES, 2018, 67
  • [23] Indirect treatment comparison of efficacy and safety of insulin glargine 300 U/mL with once-daily-insulin premix in T2DM
    Ritzel, R.
    Ghosh, S.
    Emral, R.
    Malek, R.
    Malik, R.
    Zeng, L.
    Huang, Y.
    Mabunay, M. A.
    Landgraf, W.
    Guyot, P.
    Schenk, E.
    Pushkarna, D.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [24] New insulin glargine 300 U/ml: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus
    Jeandidier, N.
    Riddle, M. C.
    Bolli, G. B.
    Home, P. D.
    Bergenstal, R. M.
    Ziemen, M.
    Muehlen-Bartmer, I.
    Wardecki, M.
    Vinet, L.
    Yki-Jarvinen, H.
    DIABETOLOGIA, 2014, 57 : S393 - S394
  • [25] NEW INSULIN GLARGINE 300 U/ML: EFFICACY AND SAFETY OF FLEXIBLE VS FIXED DOSING INTERVALS IN PEOPLE WITH TYPE 2 DIABETES MELLITUS
    Riddle, M. C.
    Bolli, G. B.
    Home, P. D.
    Bergenstal, R.
    Wardecki, M.
    Vinet, L.
    Yki-Jarvinen, H.
    Jeandidier, N.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A103 - A104
  • [26] A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine
    Dailey, G.
    Lavernia, F.
    DIABETES OBESITY & METABOLISM, 2015, 17 (12): : 1107 - 1114
  • [27] EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML (GLA-300) IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES (T2DM): A SUB ANALYSIS OF ATOS STUDY
    Khan, N.
    Al Shaikh, A. R.
    Hassoun, A.
    Mabunay, M. A. N.
    Magdy, A.
    Salah, M.
    Al Abdella, N.
    Safarini, S.
    Al Dahi, W.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A102 - A103
  • [28] A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus
    Woo, Vincent C.
    CLINICAL THERAPEUTICS, 2017, 39 (08) : S12 - S33
  • [29] Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)
    Hollander, Priscilla
    Golm, Gregory
    Carofano, Wendy
    Eldor, Roy
    Crutchlow, Michael
    Marcos, Michael
    Rendell, Marc
    Home, Philip
    Gallwitz, Baptist
    Rosenstock, Julio
    DIABETES, 2016, 65 : A238 - A238
  • [30] Cost-Effectiveness of Insulin Glargine 300 units/mL (Gla-300) vs. Insulin Degludec 100 units/mL (IDeg) in T2D
    Murphy, Daniel R.
    Yu, Xueting
    Fournier, Marie
    Klein, Timothy M.
    Fan, Tao
    Perk, Sinem
    Preblick, Ronald
    Zhou, Fang Liz
    DIABETES, 2017, 66 : A354 - A354
12345